P/E của cổ phiếu HCM là bao nhiêu?

HUTCHMED DRC (HCM) hiện giao dịch ở mức P/E 4.25 lần.

ROE của cổ phiếu HCM là bao nhiêu?

HUTCHMED DRC có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 37.01%.

Tỷ suất cổ tức của HCM là bao nhiêu?

HUTCHMED DRC có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của HCM là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của HCM ở mức 69/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu HCM không?

Điểm AI Timing của HCM là 27/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu HCM (NASDAQ) | HUTCHMED DRC

Q: Cổ phiếu HCM thuộc ngành nào?

HUTCHMED DRC được xếp vào ngành Healthcare >> Drug Manufacturers - Specialty & Generic trên sàn NASDAQ

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2025-12-31)

HCM AI Analysis Summary

Our AI summary for HCM: HUTCHMED DRC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 4.25, ROE of 37.01%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

HCM

HUTCHMED DRC

US:NASDAQ STOCK Healthcare >> Drug Manufacturers - Specialty & Generic

USD 11.13

0.36 (3.34%) Day Change

Watchlist Portfolio Compare Chart

4.25

P/E

0.08

D/E

37.0%

ROE

26.1%

ROA

0.00%

Div Yield

-0.04

PEG

HUTCHMED DRC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 11.13 Price 0.36 (3.34%) Day Change	NEWS SCORE: N/A

HCM Chất lượng tổng thể của cố phiếu Khá ( Chất lượng = 69) và Thời điểm mua ...(Sign In to See)...

Loading chart...

69 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Khá , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng

63%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	803
Magic Formula Rank by ROE	803
Magic Formula Rank by ROIC	215
Price	11.13
PBV / Sector	1.55 / 3.22 GOOD
Earning Per Share	2.62

PE / Sector	4.25 / 29.79 GREAT
PEG or PE/Growth / Sector	-0.04 / 0.13
Average 1M Daily Value	0.52 M GREAT
Average 1W Daily Value	0.46 M GREAT

Yếu tố Kỹ thuật

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

72%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	83.30 / 15.21 GREAT
NPM Average (%) / Sector	4.17 / -10.83
NPM Change Average (%) / Sector	375.65 / 117.42 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	26.13 / 8.15 GREAT
ROA Average (%) / Sector	0.48 / 2.87
ROA Change Average (%) / Sector	199.22 / 112.70 GREAT
ROE (%) / Sector	37.01 / -1.02 GREAT
ROE Average (%) / Sector	-0.84 / 8.35
ROE Change Average (%) / Sector	152.68 / 385.91 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Chi tiết đăng ký

Analyze Date	2026-08-01 07:59:57
Symbol	HCM
Name	HUTCHMED DRC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	173.81 M
Par Value	N/A
Calculated From	YearEnd
Sign	N/A
Market Cap (M.USD) / Sector Average	1,943.78 / 10,754.62

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Cheung Kong Center, Hong Kong, Hong Kong

Phone: 852 2121 8200

Website: https://www.hutch-med.com

Employees: 1,796

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.